What's breaking now, across thousands of outlets.
AHPI said that while fixing a uniform 16 per cent margin can improve transparency and affordability, it should not be treated as a one-size-fits-all solution.
We haven't written up this one. ETHealthworld has the full story — the link below goes straight to it.
New York City drug developer Kallyope is rebranding as TriGemX Bio as it focuses solely on treating migraine. To support the restructured company and its Phase 3 trials of a former Tanabe Pharma drug…
A Mayo Clinic researcher told Newsweek he's "cautiously optimistic" microbiome cancer tests are nearing clinics.
Until the BMJ demonstrate the integrity to revisit their own dismal failures regarding life and death matters, there's no reason to care about their opinions regarding less consequential issues, is…
Until the BMJ demonstrate the integrity to revisit their own dismal failures regarding life and death matters, there's no reason to care about their opinions regarding less consequential issues, is…
